3Pauwels RA, Buist AS, Calverley PM, et al. On behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management,and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary [Z] .AmJ Respir Crit Care Med.2001 Apr; 163 (5):1256 - 1276. 被引量：1
4Jarvis B, Markham A.Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease [J] .Drugs Aging.2001; 18(6): 441 - 72. 被引量：1
5Howarth PH, Beckett P, Dahl R.The effect of long acting beta2 - agonists on airway inflammation in asthmatic patients [ J ] .Respir Med.2000; 94 Supp1 F: S22 - 27. 被引量：1
6Van den Berg NJ.Salmeterol/fluticasone propionate (50/100μg) in combination in a Diskus inhaler (Seretide) is effective and sale in children with asthma [J] .Paediatric Pulmonology.2000, 10 (1): 200. 被引量：1
7Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases [ J ] .Life Sci.200321; 72 (14): 1549-61. 被引量：1
8Celli BR,MacNee W,ATS/ERS Task Force.Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946. 被引量：1
9Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.American Thoracic Society.Am J Respir Crit Care Med,1995,152(5 Pt 2):77S-121S. 被引量：1
10Postma DS,Boezen HM.Rationale for the dutch hypothesis.Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD.Chest,2004,126(2 Suppl):96S-104S. 被引量：1
10Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and a/rway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2001, 163 (2) :349-355. 被引量：1
